为何多数急性卒中研究在动物中阳性而临床失败:神经保护剂系统比较
该系统分析检索了急性缺血性卒中药物治疗的3期试验、早期临床及实验研究,比较疗效并评估发表偏倚与设计影响。结果发现阳性率从实验研究的69.08%降至早期临床32%和3期6%,平均疗效从0.76降至1.00,实验研究发表偏倚明显且把握度低,真实阳性概率不足50%。
要点
- 实验研究阳性率高但发表偏倚明显,真实阳性概率不足50%。
- 从实验到3期试验疗效逐步下降,主要与终点、治疗时间窗和设计差异有关。
- 实验研究平均把握度仅17%,质量标准和设计显著影响效应量估计。
核心结论
- 实验研究与临床试验在设计、终点、治疗时间、发表偏倚和质量标准等方面的差异导致卒中治疗疗效逐步下降。
- 即使保守估计,已发表的阳性实验卒中研究中真正阳性的不足一半。
研究设计与样本
- 系统检索并比较急性缺血性卒中药物治疗的3期试验、早期临床研究和实验研究。
- 纳入50项3期试验共46008例受试者、75项早期临床研究共12391例受试者、209项实验研究共超过7141例受试者。
主要发现
- 3期试验阳性3项(6%),早期临床研究阳性24项(32%),实验研究阳性143项(69.08%)。
- 平均治疗效应在实验研究为0.76(95%CI 0.70-0.83),早期临床为0.87(95%CI 0.71-1.06),3期试验为1.00(95%CI 0.95-1.06)。
- 漏斗图不对称和剪补法显示实验研究和早期临床研究存在明显发表偏倚。
- 实验研究平均把握度为17%,假设偏倚30%和研究前odds为0.5至0.7时,真实报告概率小于50%。
- 研究设计和对质量标准的依从性对估计效应量有相当大的影响。
关键数值与推荐
- 3期试验阳性率6%(3/50),早期临床研究阳性率32%(24/75),实验研究阳性率69.08%(143/209)。
- 实验研究平均治疗效应0.76(95%CI 0.70-0.83),早期临床0.87(95%CI 0.71-1.06),3期试验1.00(95%CI 0.95-1.06)。
- 实验研究平均把握度17%,真实报告概率小于50%。
临床怎么用
- 解读临床前卒中研究阳性结果时需考虑发表偏倚和低把握度,谨慎外推至临床。
- 临床试验设计应关注终点选择、治疗时间窗和质量标准,以缩小与实验研究的疗效差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze why numerous acute stroke treatments were successful in the laboratory but failed in large clinical trials. METHODS: We searched all phase 3 trials of medical treatments for acute ischemic stroke and corresponding early clinical and experimental studies. We compared the overall efficacy and assessed the impact of publication bias and study design on the efficacy. Furthermore, we estimated power and true report probability of experimental studies. RESULTS: We identified 50 phase 3 trials with 46,008 subjects, 75 early clinical trials with 12,391 subjects, and 209 experimental studies with >7,141 subjects. Three (6%) phase 3, 24 (32%) early clinical, and 143 (69.08%) experimental studies were positive. The mean treatment effect was 0.76 (95% confidence interval [CI] = 0.70-0.83) in experimental studies, 0.87 (95% CI = 0.71-1.06) in early clinical trials, and 1.00 (95% CI = 0.95-1.06) in phase 3 trials. Funnel plot asymmetry and trim-and-fill revealed a clear publication bias in experimental studies and early clinical trials. Study design and adherence to quality criteria had a considerable impact on estimated effect sizes. The mean power of experimental studies was 17%. Assuming a bias of 30% and pre-study odds of 0.5 to 0.7, this leads to a true report probability of <50%. INTERPRETATION: Pivotal study design differences between experimental studies and clinical trials, including different primary end points and time to treatment, publication bias, neglected quality criteria and low power, contribute to the stepwise efficacy decline of stroke treatments from experimental studies to phase 3 clinical trials. Even under conservative estimates, less than half of published positive experimental stroke studies are truly positive. ANN NEUROL 2020;87:40-51.
引用
- Schmidt-Pogoda A, Bonberg N, Koecke MHM, et al. Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. Ann Neurol. 2019. PMID: 31714631. doi:10.1002/ana.25643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。